Sung-Jae Yu

OSR Holdings Co., Ltd. is a South Korean healthcare company that develops and licenses innovative biomedical therapies based on proprietary platform technologies to address unmet medical needs. The private company is based in an undisclosed location. The company wholly-owns three operating subsidiaries focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases. OSR Holdings signed a letter of intent to acquire Landmark Bioventures AG, a Swiss company that operates through four different biotech ventures with therapeutic focuses on oncology and immunology. The company was founded in 2019, and the CEO is Sean Chung.